Breast Cancer in Young Women
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (1 November 2019) | Viewed by 14084
Special Issue Editor
2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
3. Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada
Interests: breast cancer; ovarian cancer; BRCA1; BRCA2; cancer prevention; screening
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the United States, approximately 4.4% of breast cancers are diagnosed in women younger than 40, and these cases account for 2.5% of breast cancer deaths. These statistics actually underestimate the impact of early-onset breast cancer, because of all women who die from breast cancer, 8.6% are diagnosed before age 40. Little is known about the etiology of this disease, as the incidence of breast cancer in individuals aged under 40 is stable for women worldwide, but the mortality rate varies widely. The proportion of young women who have a genetic predisposition to breast cancer may be 20% or greater.
The poor prognosis of women with early-onset breast cancer is reflected, to some extent, by the relatively high proportion of young women who present with distant metastases and relatively poor pathologic features; however, stage and grade do not tell the whole story. Breast cancer-related deaths in young women are largely restricted to ER-positive cases. It is of interest that ER status is not a favorable marker for prognosis for young women, and it is important to determine whether other prognostic markers are associated with poor outcomes in this subgroup of women, and, in particular, if they can be used to determine the need for chemotherapy. However, caution should be exercised if chemotherapy is to be with-held from young women on the basis of prognosis. Further, treatment of this condition in young women is complicated by the fact that they may wish to have children after treatment; this raises concerns about optimizing treatment and maintaining fertility at the same time considering the possible teratogenic and toxic effects of current treatments. In the current issue, we explore topics related to breast cancer occurring in women before age 40.
Dr. Steven Narod
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
